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The objective of this study was to compare the safety of all modified live virus vaccines commercially available in
Europe against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) under the same experimental
conditions. For this purpose, one hundred and twenty three-week-old piglets, divided into five groups, were used.
On day 0 of the experiment, nine pigs per group were removed and the remaining fifteen were vaccinated with
the commercial vaccines Ingelvac PRRS MLV, Amervac PRRS, Pyrsvac-183 and Porcilis PRRS by the IM route or were
mock vaccinated and used as controls. On day 3, the nine unvaccinated pigs were re-introduced into their respective
groups and served as sentinel pigs. Clinical signs were recorded daily and lung lesions were determined on days 7, 14
and 21, when 5 vaccinated pigs per group were euthanized. Blood samples and swabs were taken every three days
and different organs were collected at necropsy to determine the presence of PRRSV. None of the vaccines studied
caused detectable clinical signs in vaccinated pigs although lung lesions were found. Altogether, these results indicate
that all vaccines can be considered clinically safe. However, some differences were found in virological parameters.
Thus, neither Pyrsvac-183 nor Porcilis PRRS could be detected in porcine alveolar macrophage (PAM) cultures or in lung
sections used to determine PRRSV by immunohistochemistry, indicating that these viruses might have lost their ability
to replicate in PAM. This inability to replicate in PAM might be related to the lower transmission rate and the delay in
the onset of viremia observed in these groupsIntroduction
Porcine Reproductive and Respiratory Syndrome (PRRS)
is an economically significant disease of pigs that causes
respiratory distress in piglets and reproductive failure in
sows [1,2]. The causal agent, PRRS virus (PRRSV), is a
small, enveloped, single-stranded positive-sense RNA
virus of the Arteriviridae family [3]. Although, in gen-
eral, PRRS is clinically similar in North America and
Europe, the respective strains differ in virulence [4,5]
and in antigenic [6,7] and genetic [8] properties. These
differences have led to the classification of PRRSV iso-
lates into two genotypes: type 1 that comprises viruses
related to the European prototype Lelystad-virus and* Correspondence: cprietos@vet.ucm.es
1Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad
Complutense de Madrid, Avda. Puerta de Hierro s/n, 28040 Madrid, Spain
Full list of author information is available at the end of the article
© 2013 Martínez-Lobo et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumtype 2 that includes viruses related to the American
prototype strain VR-2332 [8].
The huge impact of PRRS in the swine industry has
stimulated the development of various types of vaccines,
including inactivated and modified-live virus (MLV)
vaccines, for the control of the disease in both growing
pigs and breeding females. MLV vaccines based on type
1 and type 2 viruses were originally developed for the
control of PRRS in growing pigs, although some of them
are now registered for the control of the reproductive
form of PRRS. However, the safety of these products has
been questioned based on the results of some experi-
mental studies and on field evidence. Thus, experimental
studies carried out with Ingelvac PRRS MLV, a vaccine
based on a type 2 isolate, have demonstrated that vac-
cine virus replicates in vaccinated pigs, causes detectable
viremia, persists in the organism of vaccinates for weeks
[9-11] and is shed by different routes causing theCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cross the placental barrier in pregnant sows infecting the
developing fetuses [13] and can be transmitted to naïve
newborn piglets during lactation [14]. Even more, rever-
sions to virulence have been suspected in the field based
on the similarity between the vaccine strain and some
strains that have caused clinical problems in areas where
the vaccine has been used, regardless of whether the
affected animals had been vaccinated or not [15,16].
Despite the knowledge in relation to the safety of type
2 Ingelvac PRRS MLV vaccine, not much information
has been published about the safety of MLV vaccines
based on type 1 PRRS viruses, even though they are fre-
quently used for the control of the disease in several
European countries. In fact, there are only a few reports
that demonstrate that these vaccines replicate in the host
causing viremia during variable periods of time both in
growing pigs [17] and in breeding females [18], which
can lead to transplacental infection of fetuses [18]. How-
ever, no information is available regarding the ability of
these vaccine strains of being shed and transmitted to
in-contact pigs.
Even more, the above mentioned studies have been
carried out under different conditions, using different
experimental models, i.e. growing pigs versus breeding
females, and different experimental designs, with differ-
ences affecting not only the age of vaccinated pigs but
also the quality and quantity of the parameters mea-
sured. Under these circumstances, the information avail-
able about the safety of different vaccines is only partial
and direct comparison of the results between different
experiments is not feasible, making it impossible to de-
termine whether different vaccine strains differ in their
safety properties. Consequently, the objective of the
present study was to elucidate and compare the safety
of all MLV vaccines commercially available in Europe
under the same experimental conditions, measuring
their ability to induce clinical signs and lung lesions,
their replication capacity in the host, their ability to be




One hundred and one hundred and twenty three-week-
old crossbred conventional piglets seronegative for
PRRSV, Mycoplasma hyopneumoniae and negative by
PCR for porcine circovirus type 2 (PCV2) were used in
this study. The animals were randomly divided into five
groups (A to E) of twenty-four animals each and housed
in isolation in pens with a concrete floor and an auto-
matic watering system.
All experimental procedures were approved by the
Animal Ethics Committee of the Universidad Complutensede Madrid and were conducted in accordance with the
guidelines of the Good Experimental Practices (GEP)
standard adopted by the European Union, which ensure
the protection and welfare of the animals used in research.
Vaccines and cell cultures
The experiments were performed with all MLV vaccines
registered in Europe: Ingelvac PRRS MLV (Boehringer
Ingelheim, USA); Porcilis PRRS (Merck, Sharp and
Dohme Animal Health, USA, formerly Intervet S.A., The
Netherlands); Amervac PRRS, (Laboratorios Hipra S.A.,
Spain) and Pyrsvac-183 (Laboratorios Syva, S.A., Spain).
The first one belongs to type 2 PRRSV while the other
three are based on subtype I of type 1 PRRSV strains,
although of two different clades. Thus, Porcilis PRRS
strain has been classified in clade A of subtype I while
Amervac PRRS strain and Pyrsvac-183 strain belong to
clade D of the same subtype [19]. The parent strains
of these vaccines, i.e. VR2332 (Boehringer Ingelheim),
VP-046 bis (Amervac PRRS), All-183 (Pyrsvac-183) and
AD (Porcilis PRRS), were isolated in the USA in 1992, in
Spain in 1992 and 1991 and in The Netherlands in 1992,
respectively.
The presence of PRRSV in clinical samples obtained
from experimental pigs was determined by culturing the
samples in the MARC-145 cell line, a cell clone highly
permissive for PRRSV derived from the MA-104 cell line
[20], and in porcine alveolar macrophages (PAM), pre-
pared and maintained as previously described [21].
Experimental design and sample collection
On day 0 of the experiment, after an acclimatization
period of 7 days, nine animals per group were removed
and the remaining fifteen pigs of groups A to D were
vaccinated with the commercial vaccines Ingelvac PRRS
MLV, Amervac PRRS, Pyrsvac-183 and Porcilis PRRS,
respectively, by the IM route following the manufac-
turers’ instructions. Finally, fifteen pigs of Group E were
mock vaccinated using a MARC-145 cell culture super-
natant as the inoculum. On day 3 of the experiment, the
nine unvaccinated pigs were re-introduced into their re-
spective experimental groups and served as sentinel pigs.
During the whole experimental period, vaccinated and
in-contact pigs were examined daily for clinical signs
following a previously published clinical score system [5]
and rectal temperatures and food intake were recorded
starting 3 days before vaccination. Blood samples were
collected in serum-clot vacuum tubes on days 0, 3, 6, 9,
12, 15 and 18 of the experiment from vaccinated pigs
and on days 3, 6, 9, 12, 15, 18 and 24 from in-contact
pigs. Serum was obtained and stored at −80 °C until use
for virus isolation and to measure antibodies against
PRRSV. In addition, blood samples obtained from senti-
nel pigs, were used to determine the presence of PRRSV
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the principal group as soon as they were detected to be
viremic. Nasal, oral and rectal swabs were obtained from
vaccinated pigs on the days of blood collection, immersed
in 2 mL of Dulbecco’s modified eagle’s medium (DMEM)
and stored at −80 °C until processed for virus isolation.
Pigs were weighed on each bleeding day. Daily weight
gains (DWG) were estimated for each pig for three differ-
ent periods: from day 0 to day 6; from day 7 to day 15 and
from day 16 to day 21 post-vaccination (pv).
On days 7, 14 and 21 of the experiment, five vaccinated
pigs per group and five controls were euthanized by an
overdose of sodium pentobarbital (Dolethal, Vetoquinol,
France) dosed by intravenous route (IV) and a complete
necropsy was performed. Samples of lung, tonsil, thymus,
ileum and submandibular, superficial inguinal, sternal, me-
diastinal and mesenteric lymph nodes were collected and
stored at −80 °C until use for virus isolation. In addition,
lung samples were taken for histopathological studies.
Blood samples, nasal, oral and rectal swabs were obtained
at necropsy, stored at −80 °C and processed for virus isola-
tion. On day 24 of the experiment all in-contact pigs were
euthanized.Virus isolation and titration
Clinical samples were processed as described elsewhere
[21] and were used to inoculate monolayers of PAM and
MARC-145 cells in quadruplicate. Cell cultures were in-
cubated for 90 min at 37 °C to facilitate adsorption,
washed twice with culture media and fresh DMEM sup-
plemented with 10% fetal bovine serum (FBS) was
added. Then, cell cultures were incubated for 6 days at
37 °C in a humidified atmosphere containing 5% CO2
and the presence of cytopathic effect (CPE) typical of
PRRSV was evaluated on days 4 to 6. As a positive con-
trol, strain 5710 was added to PAM cultures to a final
concentration of 103, 102 and 10 TCID50/well [21]. Only
batches of PAM with a minimum sensitivity to infection
of at least 50% of the wells to which 10 TCID50 were
added were used. Virus-free DMEM or FBS were used
as negative controls. If CPE was observed, RT-PCR was
carried out as previously described [22] to confirm the
presence of PRRSV.
Virus titers were determined as described by Prieto
et al. [21]. Titers were calculated as described by Reed
and Muench [23], and expressed as TCID50/g for tissue
samples or TCID50/mL for serum or fluid samples.Serological examination
Serum samples obtained from vaccinated and in-contact
pigs were examined for PRRSV-specific antibodies using
a commercial ELISA test (HerdChek PRRS ELISA 2XR,
IDEXX Laboratories, Inc. Westbrook, MA, USA).Pathological examination
At necropsy, all organs were examined with emphasis on
the respiratory tract. Lungs were given a score to esti-
mate the percentage of lung surface affected, using a
scoring system previously reported to evaluate gross
lung lesions [4].
Lung samples (including apical, cardiac and diaphrag-
matic lobes) were collected and fixed by immersion in
10% neutral buffered formalin. Subsequently, pulmonary
tissues were dehydrated through graded alcohol and
embedded in paraffin wax. Two consecutive 4 μm thick
sections were cut. One of them was stained with
hematoxylin-eosin (HE) and the other one was proc-
essed to detect PRRSV antigen by immunohistochemis-
try. Lung sections were examined in a blinded fashion
and an estimate score of the severity of the interstitial
pneumonia based on a previously published scoring
system [4] was given.Immunohistochemistry
PRRSV immunohistochemistry was based on a previ-
ously published procedure [24], using as primary anti-
body monoclonal antibody 1 AC7 (Ingenasa, Madrid,
Spain), specific for nucleocapsid protein (N) of both
PRRSV genotypes. Antigen amount was given a ranked
score of 0 to 3 as an estimate of the number of foci of
positive cells per section of tissue taken from each animal
(three lung pieces examined): 0 = no PRRSV-antigen-
positive cells; 1 = 1–5 foci of positive cells; 2 = 5–10 foci
of positive cells; 3 = >10 foci of positive cells. A focus of
positive cells was defined as an area studied at 400× field
magnification in which at least 3–5 positive cells were
observed. The scoring was also done in a blinded fashion
by the same pathologist.Statistical analysis
The occurrence of clinical signs over the entire post-
vaccination period, gross and microscopic lung lesions
at necropsy and the viral determination by immunohis-
tochemistry were evaluated for significance using the
Kruskal-Wallis’s non-parametric test and Mann–Whitney
U test. Differences in viral load and serological (S/P ratio)
values at each sampling point were analyzed using a one-
way analysis of variance and the Duncan’s multiple range
test. A Student’s t test was used to assess significance
in differences in rectal temperatures prior to and after
vaccination in each experimental group. Differences in the
proportions of positive clinical samples and of in-contact
pigs infected in each experimental group were assessed for
significance by the 2-tailed Fisher’s exact test. In the evalu-
ation of virological parameters only data of groups A to D
were compared while in the evaluation of clinical or pro-
ductive parameters data of all five groups were compared.
Table 1 Macroscopic lung lesion scores recorded for each
experimental group in each day of necropsy.
Groups Necropsy day
Day 7 pv Day 14 pv Day 21 pv
A 0.5 ± 0.9a 1.4 ± 1.1 2.3 ± 2.4
B 2.2 ± 1.6 1.6 ± 2.2 0.6 ± 0.9
C 2.4 ± 3.3 0.0 ± 0.0 0.0 ± 0.0
D 0.7 ± 0.8 0.7 ± 1.1 0.0 ± 0.0
E 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
a mean ± standard deviation of macroscopic lung lesion scores.
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Clinical signs and growth performance
Control pigs and vaccinated animals of groups A, B, C
and D remained in good health and condition after vac-
cination and no local or general adverse reactions were
observed. Thus, no clinical signs were recorded for any
pig during the experiment. Rectal temperatures remained
within physiological values during the whole experimental
period and no statistically significant increases were ob-
served after vaccination in any group. All in-contact pigs
remained in normal health and condition throughout the
experiment, and neither clinical signs nor fever were re-
corded. Average DWG (ADWG) for each experimental
group in the different periods analyzed is depicted in
Figure 1. As observed in the figure, ADWG increased over
time, regardless of the group considered. However, no sta-
tistically significant differences were observed between
groups at any time.
Macroscopic lung lesions
Gross lung lesions were never recorded in pigs of Group
E, regardless of the day of necropsy. On the contrary,
lesions characterized by multifocal, tan-mottled areas of
pneumonia were found in all other experimental groups.
However, there were significant individual variations.
Thus, in some pigs no lesions were recorded and in
others lesions were very mild. The mean percentages of
affected lung surface in pigs of each experimental group
at each necropsy day are shown in Table 1. The percent-
age of affected lung surface was dependent on the vac-
cine strain used as the inoculum. Pigs exposed to type 1
PRRSV showed mild (Groups B and C) to insignificant
(Group D) lung lesions on day 7 pv with percentages of
affected lung surface ranging from 0.7% to 2.4%. These
lesions tended to resolve in the following days, leading
to unremarkable lung lesions on day 21 pv. On the con-
trary, pigs of Group A, vaccinated with a type 2 PRRSFigure 1 Average Daily Weight Gain (ADWG) recorded for vaccinated
every three days. Individual weights of days 0, 6, 15 and 21 were used to estimvaccine strain, had the less extensive lung lesions on day
7 pv and afterwards the percentage of affected lung sur-
face increased, reaching its maximum values on day
21 pv. However, when the percentages of affected lung
surface were compared, no statistically significant differ-
ences were observed between groups.
Microscopic lung lesions
No microscopic lung lesions were recorded in any of the
control pigs. However, some pigs of all other experi-
mental groups developed interstitial pneumonia cha-
racterized by multifocal to diffuse, slight to moderate
thickening of the alveolar wall with variable amounts of
macrophages between alveoli. The severity of the inter-
stitial pneumonia observed in vaccinated pigs globally
increased over time, peaking the mean score values at
21 days pv. The number of pigs with microscopic lesions
and the mean pathological score plus standard devia-
tions of all experimental groups at different necropsy
days are given in Table 2. The number of pigs showing
microscopic lung lesions was lower in groups C and D
than in groups A and B. However, differences between
groups were statistically significant only when groups A
and B were compared to groups C and E on day 21 pv
(P < 0.05). Likewise, the severity of the lesions recordedpigs of all experimental groups. All vaccinated pigs were weighted
ate the ADWG of each group in periods 0 to 6; 7 to 15 and 16 to 21.
Table 2 Microscopic lung lesion scores recorded for each
experimental group in each day of necropsy.
Group Necropsy day
Day 7 pv Day 14 pv Day 21 pv
A 0.2 ± 0.4a 0.0 ± 0.0 1.6 ± 0.5
B 0.0 ± 0.0 0.4 ± 0.5 1.2 ± 0.4
C 0.0 ± 0.0 0.0 ± 0.0 0.2 ±0.4
D 0.2 ± 0.4 0.0 ± 0.0 0.4 ± 0.5
E 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
a mean ± standard deviation of microscopic lung lesion scores.
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moderate (score 2) or mild (score 1) in pigs of groups A
and B while they were always mild (score 1) in pigs of
groups C and D. However, differences in the severity of
the microscopic lung lesions were statistically significant
only when Group A was compared to groups C, D and
E (P < 0.05) and when Group B was compared to groups
C and E (P < 0.05) on day 21 pv.
Detection of PRRSV in vaccinated pigs
Viremia
Viremia was never detected in any control pig, regard-
less of the cell culture type used as support for viral
replication. The results of virus isolation from serum
samples collected at different days post-vaccination from
pigs of groups A to D are summarized in Table 3. All
vaccine strains induced viremia in vaccinated pigs, al-
though the number of positive pigs varied depending on
the group, the day considered and the cell type used for
virus isolation. When virus isolation was attempted on
MARC-145 cell cultures most animals were positive
from day 3 onwards on groups A and B, while viremia
was detected only from day 6 onwards in pigs of groups
C and D. The differences in the onset of viremia wereTable 3 Results of virus isolation from serum samples of vacc
Days post-
vaccination
Virus isolation on Marc-145
Group
A B C
0 0/15 (0) a 0/15 (0) 0/15 (0)
3 12/15 (80) 14/15 (93.3) 0/15 (0)
6 15/15 (100) 14/15 (93.3) 14/15 (93.3) 1
7 5/5 (100) 5/5 (100) 5/5 (100)
9 10/10 (100) 8/10 (80) 6/10 (60)
12 10/10 (100) 8/10 (80) 9/10 (90)
14 5/5 (100) 4/5 (80) 3/5 (60)
15 5/5 (100) 5/5 (100) 3/5 (60)
18 5/5 (100) 4/5 (80) 4/5 (80)
21 5/5 (100) 4/5 (80) 4/5 (80)
a Number of positive samples/Number samples tested (Percentage of positive sampstatistically significant (P < 0.05). Even more, the total
number of positive serum samples obtained after vaccin-
ation varied depending on the group considered (i.e. 96%
for pigs of Group A; 88% for pigs of Group B; 64% for pigs
of Group C and 57.3% for pigs of Group D). When virus
isolation was carried out on PAM cultures most of the
samples tested were negative, regardless of the group con-
sidered. Only three samples from pigs of Group A (4.0%)
and five samples from pigs of Group B (6.67%), all of them
obtained from 12 days pv onwards, were positive.
The mean viral titers of serum samples positive by
virus isolation in MARC-145 cell cultures were calcu-
lated and are depicted in Figure 2. Viral titers varied
slightly depending on the group and day of the experi-
ment considered. The highest mean viral titers in serum
samples were obtained in pigs of Group A in the last
week of the experiment. On the contrary, mean viral
titers tended to be lower in serum samples of pigs of
Group C than in any other group during the whole
experimental period. However, no statistically significant
differences were observed in mean viral titers between
groups at any time. Viral titers were also calculated for
serum samples positive in PAM cultures. The mean titer
of those samples was very low, barely above the detec-
tion limit (data not shown).
Organic distribution
The results of virus isolation in MARC-145 cell cultures
from different tissue samples collected at different days
of necropsy from vaccinated pigs of Groups A, B, C and
D are shown in Table 4. All tissue samples obtained
from control pigs were negative by virus isolation. On
the contrary, PRRSV was isolated from at least one
tissue sample of all vaccinated pigs, regardless of the
group they belonged to or the day of necropsy. However,
the frequency of PRRSV isolation varied depending oninated pigs in MARC-145 and PAM cultures.
Virus isolation on PAM
Group
D A B C D
0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0)
0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0)
1/15 (73.3) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0)
3/5 (60) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
8/10 (80) 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
8/10 (80) 1/10 (10) 3/10 (30) 0/10 (0) 0/10 (0)
4/5 (80) 1/5 (20) 1/5 (20) 0/5 (0) 0/5 (0)
3/5 (60) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
4/5 (80) 0/5 (0) 1/5 (20) 0/5 (0) 0/5 (0)
2/5 (40) 1/5 (20) 0/5 (0) 0/5 (0) 0/5 (0)
les).
Figure 2 Mean viral titers in positive serum samples of vaccinated pigs at each sampling day. Titers are expressed as tissue culture
infectious doses 50 (TCID50) per mL of serum. Bars represent the standard deviation.
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frequently isolated from tonsils, with 49 out of 60 posi-
tive samples (81.7%), than from any other sample. On
the contrary, the organ from which PRRSV was less fre-
quently isolated was the spleen, with only 13 out of 60
positive samples (21.7%).
When the percentage of positive samples was compared
between groups it was observed that the frequency of
isolation of PRRSV from tissue samples was higher
in samples of pigs of Group B than in any other group,
being the global percentage of positive organs 64.4%Table 4 Results of virus isolation from tissue samples of vacci
Organ Group A Group B
Days post-vaccination Days post-vaccination
7 14 21 Totalb 7 14 21 Tot
Lung 0/5a 3/5 5/5 53.3 3/5 4/5 3/5 66
Tonsil 5/5 4/5 5/5 93.3 4/5 4/5 5/5 86
Ileum 3/5 1/5 2/5 40 4/5 2/5 3/5 60
Thymus 1/5 0/5 3/5 26.7 2/5 3/5 3/5 53
Spleen 0/5 0/5 1/5 6.7 2/5 3/5 4/5 60
Mes. L.N. 3/5 0/5 0/5 20 2/5 3/5 4/5 60
Med. L.N. 4/5 1/5 2/5 46.7 5/5 2/5 4/5 73
L.S.L.N. 2/5 1/5 3/5 40 3/5 4/5 5/5 8
R.S.L.N 2/5 1/5 3/5 40 5/5 4/5 5/5 93
L.S.I.L.N. 2/5 1/5 2/5 33.3 1/5 2/5 4/5 46
R.S.I.L.N. 3/5 2/5 3/5 53.3 1/5 3/5 3/5 46
Est.L.N. 1/5 2/5 4/5 46.7 1/5 2/5 4/5 46
Totalb 43.3 26.7 55.0 41.7 55.0 60.0 64.4 64
a Number of positive samples/total number of samples; b Percentage; Mes.L.N: Mese
Submandibular Lymph Node; R.S.LN: Right Submandibular Lymph Node; L.S.I.L.N.: L
Node; Est.L.N.: Esternal Lymph Node.compared to 41.7%, 37.8% and 33.9% in groups A, C and
D, respectively. These differences were statistically signifi-
cant (P < 0.05). However, when the frequency of isolation
from different organs analyzed in the study was compared
between groups, differences were not statistically signifi-
cant, probably due to the low number of pigs per group.
The only exception was the frequency of PRRSV isolation
from spleen samples, which was significantly higher in
pigs of group B (P < 0.05) than in any other group.
The viral load in tissue samples positive by virus isola-
tion on MARC-145 was calculated and the mean valuesnated pigs in MARC-145 cultures.
Group C Group D
Days post-vaccination Days post-vaccination
alb 7 14 21 Totalb 7 14 21 Totalb
.7 0/5 1/5 2/5 20 1/5 2/5 2/5 33.3
.7 4/5 4/5 5/5 86.7 2/5 4/5 3/5 60.0
.0 2/5 1/5 2/5 33.3 2/5 2/5 1/5 33.3
.3 1/5 0/5 2/5 20 2/5 2/5 1/5 33.3
.0 0/5 1/5 0/5 6.7 0/5 2/5 0/5 13.3
.0 2/5 2/5 2/5 40 1/5 1/5 0/5 13.3
.3 4/5 3/5 3/5 66.7 2/5 3/5 0/5 33.3
0 2/5 4/5 3/5 60 2/5 2/5 2/5 40.0
.3 1/5 4/5 4/5 60 2/5 3/5 2/5 46.7
.7 0/5 1/5 1/5 13.3 1/5 3/5 1/5 33.3
.7 0/5 2/5 3/5 33.3 1/5 3/5 1/5 33.3
.7 0/5 1/5 1/5 13.3 2/5 3/5 0/5 33.3
.4 26.7 40.0 46.7 37.8 30.0 50.0 21.7 33.9
nteric Lymph Node; Med.L.M.: Mediastinic Lymph Node; L.S.L.N.: Left
eft Superficial Inguinal Lymph Node; R.S.I.L.N.: Right Superficial Inguinal Lymph
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higher in tonsils than in any other tissue regardless of
the group considered as observed in the Figure. How-
ever, differences in viral titer between organs in each
particular group and in the same organ between groups
were not statistically significant.
When virus isolation was performed in PAM cultures,
PRRSV was only recovered from two tonsils of animals
from Group A and four tonsils of pigs from Group B, all
of them on day 21 pv. The viral titer of positive samples
was very low, barely above the detection limit (data not
shown).
Immunohistochemistry
PRRSV antigen was never detected by IHC in any lung
section of control pigs. However, it was detected in some
samples of vaccinated pigs. Nonetheless, the number of
positive pigs was very low, as was the number of positive
foci found in positive samples, which led to very low
mean score values. Thus, all samples from pigs of groups
C and D were negative by IHC, as well as all samples
obtained from pigs of groups A and B on days 7 and
14 pv. However, on day 21 pv 3 out of 5 samples obtained
from pigs of Group A and 2 out of 5 samples obtained
from pigs of Group B were positive by IHC, all of them
with a score of 1. When PRRSV antigen was detected, it
was primarily found within the cytoplasm of macrophages
in the alveolar space.
Virus shedding
The results of PRRSV isolation from different body
fluids collected at intervals after vaccination from vacci-
nated pigs are summarized in Table 5. As expected, all
samples collected from negative controls were negativeFigure 3 Mean viral titers in positive tissue samples of vaccinated pig
infectious doses 50 (TCID50) per gram of tissue. Bars represent the standard
lymph node; LSILN: left superficial inguinal lymph node; RSILN: right superf
mediastinic lymph node; Mes.LN: mesenteric lymph nodeby virus isolation. However, all vaccine strains studied
could be detected in all secretions analyzed, although
the frequency of shedding varied slightly depending on
the route considered. Thus, the presence of PRRSV was
relatively common in oropharyngeal secretions from day
6 to day 15 pv and sporadic thereafter, with a total per-
centage of positive samples of 8.33%. On the contrary,
the virus was detected more sporadically in nasal secre-
tions, with a global percentage of positive samples of
4.67%, although shedding started earlier (i.e. day 3 pv)
and lasted until day 18 pv. Finally, in feces PRRSV could
be detected from day 6 pv until the end of the experi-
ment, with a percentage of positive samples of 5.67%.
Differences in the frequency and duration of shedding
depended on the vaccine tested. The highest number of
positive samples was obtained in pigs of Group A (18 in
total, which represents 8.0% of the samples taken after vac-
cination) and the lowest number in Group D (11 positive
samples, meaning 4.89%), being groups B and C in inter-
mediate positions (12 and 15 positive samples, i.e. 5.33%
and 6.67%, respectively). Nonetheless, differences in the
number and distribution of positive samples were not
statistically significant. Virus titer in positive samples was
not determined.
Seroconversion of vaccinated pigs
Pigs of Group E remained seronegative until the end of
the study. Among vaccinated pigs euthanized on day
7 pv, PRRSV specific antibodies were detected only in
one pig of Group C. However, several pigs of different
groups were already seropositive on day 12 pv and the
number of seropositive animals among those euthanized
on day 14 pv was 5, 3, 4 and 5 for groups A, B, C and D,
respectively. Finally, on day 21 pv all pigs, regardless ofs at each necropsy day. Titers are expressed as tissue culture
deviation. LSLN: left superficial lymph node; RSLN: right superficial
icial inguinal lymph node; Est.LN: esternal lymph node; Med.LN:
Table 5 Results of virus isolation from different swabs collected from principal pigs in MARC-145 cells.
Days of
the experiment
Nasal swabs Oral swabs Rectal swabs
Group Group Group
A B C D A B C D A B C D
0 0/15a 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15
3 1/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15 0/15
6 1/15 0/15 1/15 2/15 2/15 1/15 3/15 1/15 0/15 0/15 0/15 0/15
7 2/5 1/5 1/5 0/5 1/5 1/5 0/5 1/5 2/5 1/5 1/5 1/5
9 0/10 0/10 0/10 0/10 1/10 0/10 2/10 1/10 2/10 2/10 1/10 1/10
12 0/10 0/10 2/10 0/10 0/10 0/10 1/10 1/10 0/10 1/10 0/10 1/10
14 0/5 0/5 1/5 0/5 0/5 3/5 1/5 0/5 0/5 0/5 1/5 1/5
15 1/5 0/5 0/5 0/5 2/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5
18 0/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5 1/5 0/5 0/5 0/5
21 0/5 0/5 0/5 0/5 1/5 0/5 0/5 1/5 1/5 0/5 0/5 0/5
Total 5/90 2/90 5/90 2/90 7/90 6/90 7/90 5/90 6/90 4/90 3/90 4/90
a Number of positive samples/Number of samples tested.
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the slight differences in the timing of seroconversion, no
statistically significant differences were detected between
groups in the number of seropositive pigs or in the S/P
ratio values of seropositive pigs.
Transmission of vaccine strains to sentinel pigs
Viremia
The results of virus isolation in MARC-145 cell cultures
from serum samples collected from sentinel pigs of groups
A, B, C and D at different times of the experiment are
shown in Figure 4. All vaccine strains were able to induce
viremia in the sentinel pigs; however, the percentage of
viremic pigs varied depending on the vaccine strain and
the day of the experiment considered. Thus, viremia was
detected from day 9 to the end of the experiment in at
least some of the sentinel pigs of Group A and all of them
were viremic on day 18. Viremia was detected earlier in
pigs of Group B (one sentinel pig was already viremic on
day 6 of the experiment in this group) and the virus was
detected in most of the sentinel pigs from day 12 to the
end of the experiment. However, there was one pig that
was never viremic. On the contrary, most sentinels of
groups C and D remained negative by virus isolation until
the end of the experiment. In Group C only two animals
(22.2%) were viremic from day 9 to the end of the experi-
ment. In Group D viremia was detected at least once in
four sentinel pigs (44.4%) and in this group viremia tended
to be shorter, with only one viremic sentinel pig on day
24. The differences in the percentage of viremic sentinel
pigs were statistically significant when the results of Group
A were compared to the results of groups C and D on
days 18 and 24 of the experiment (P < 0.05), and also when
the results of Group B were compared to the results of
Group C on day 18 (P < 0.05).When virus isolation from serum samples of sentinel
pigs was performed in PAM cultures, PRRSV was recov-
ered from a limited number of samples; particularly from
two pigs of Group A on day 21 of the experiment and
from one pig of Group B on day 18 of the experiment.
Viral load of positive samples ranged from 1.8 TCID50/
mL to 3.6 TCID50/mL, depending on the group and day
of the experiment considered. However, no statistically
significant differences were found between groups (data
not shown).
Seroconversion
Seroconversion of sentinel pigs was not detected until
day 15 of the experiment, when two sentinel pigs of
Group B were seropositive (Figure 5). On day 18, the
number of seropositive sentinel pigs in Group B had
increased to five and, additionally, five sentinel pigs of
Group A and one sentinel pig of Group D were sero-
positive. Finally, at the end of the experiment, on day 24,
seven, eight, one and four sentinel pigs of groups A, B,
C and D, respectively, had seroconverted.
Viral shedding
Infected sentinels shed vaccine viruses by different
routes, although the frequency of shedding varied be-
tween groups and routes considered (Figure 6). Vaccine
virus was detected in 12 out of 102 (11.77%) samples ob-
tained from infected sentinel pigs of Group A, all of
them between day 9 and day 24 of the experiment. In
this group, the virus was more frequently shed in nasal
secretions, followed by oral secretions and only sporad-
ically in feces. On the contrary, PRRSV was more fre-
quently isolated from fecal samples of infected sentinels
of Group B than from any other sample, with 4 out of
35 positive samples, while only one nasal swab and one
Figure 4 Proportion of viremic sentinel pigs from each experimental group in each sampling day. Blood samples were taken from
sentinel pigs every three days. The percentages of sentinel pigs found viremic in each experimental group in each sampling day are represented
in the figure.
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from infected sentinel pigs of Group B were positive.
Finally, PRRSV was very rarely isolated from sentinel
pigs of groups C and D with only one out of 30 samples
(i.e. 3.33%) and one out of 45 samples (i.e. 2.22%), re-
spectively taken from infected pigs rendering a positive
result.
Discussion
The major impact of PRRSV on pig production has
stimulated the development of various types of vaccines,
including inactivated virus and MLV vaccines for the
control of the disease. However, only a limited number
of controlled studies have been carried out to demonstrateFigure 5 Proportion of PRRSV seropositive sentinel pigs from each ex
pigs was assessed by ELISA test. The percentage of sentinel pigs positive b
represented in the figure.the safety of MLV vaccines based either on type 1 or type
2 PRRSV strains [9,13,14,18,25]. Most of these studies
have been designed to prove the safety of one or two com-
mercially available vaccines and no comparative studies
have ever been carried out. Moreover, the comparison of
the results of the different research studies is difficult be-
cause they have used diverse experimental designs, age,
breeds and health status of pigs. To obtain information
that allows comparisons, we investigated the safety of
four different MLV vaccine strains available in different
European countries under the same experimental condi-
tions in a young pig model (i.e. 28 day-old). Our criterion
to evaluate MLV vaccine safety in this model was based on
the severity of clinical signs, gross and microscopic lungperimental group in each sampling day. Seroconversion of sentinel
y ELISA test in each experimental group in each sampling days are
Figure 6 Percentage of PRRSV positive swabs obtained from infected sentinel pigs during the experiment. Oral, rectal and nasal swabs
were obtained from sentinel pigs every three days. Swabs from sentinel pigs considered to be infected (based on the determination of viremia in
the same days or in previous days) were used for virus isolation. The percentage of positive swabs obtained from infected pigs in each
experimental group each sampling day is represented in the figure.
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tissues, shedding of the vaccine strains and transmission
rate to sentinel pigs.
The results of our study indicate that some differences
can be established in the safety of the four MLV vaccines
compared, although not in all parameters evaluated.
Thus, no differences were observed in relation to the in-
duction of clinical signs or in the productive perform-
ance of pigs of the different experimental groups. In fact,
no clinical signs were recorded for any pig during the
complete experimental period. The absence of clinical
signs, and specifically of respiratory clinical signs, was
consistent with the recording of slight to moderate gross
lung lesions at necropsy, regardless of the group consid-
ered. Although, the percentage of affected lung surface
can be considered similar in all experimental groups, in
pigs exposed to type 1 MLV vaccine strains, macroscopic
lung lesions resolved over time while in pigs exposed to
type 2 PRRSV strain the percentage of affected lung surface
increased over time until the end of the experiment. Thispicture is coincident with previous findings comparing type
1 and type 2 field strains that indicate that macroscopic
lung lesions produced by type 2 PRRSV isolates tend to be
more persistent and last longer than those produced by
type 1 PRRSV isolates [5]. Thus, it is likely that the pattern
of onset and resolution of lesions observed in the present
study are more related to the genotype of the parent
strains of the vaccine viruses than to changes occurring
during the attenuation process. However, since the patho-
physiologic characteristics of the parent strains of each of
the vaccine strains tested in this study could not be deter-
mined, we cannot completely rule out the influence of the
attenuation process in the incidence and evolution of lung
lesions.
The mildness of macroscopic lung lesions recorded
resulted in a low frequency and severity of microscopic
lung lesions, although, on the contrary to what was
observed with macroscopic lung lesions, they increased
over time in all groups. The persistence of microscopic
lung lesions when macroscopic changes are mild or
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ported by others [5,24] and seems to be typical of
PRRSV infection. Differences in the frequency and sever-
ity of microscopic lung lesions were statistically signifi-
cant between groups on day 21 pv, when the number of
pigs with lesions was the greatest and the severity of
those lesions was the highest. These differences might
be due to, at least, two different reasons. On the one
hand, differences in the intrinsic characteristics of the
parent strains and, in particular, in their pneumotropism
and pathological effects in the host may be behind the
differences found in the frequency and severity of micro-
scopic lung lesions. These differences have been previ-
ously described when the virulence of different wild-type
PRRSV has been compared in a young pig infection
model [4,5,26]. On the other hand, the attenuation
process might have changed the tropism of the viruses
and limited their ability to replicate in the lung and
cause lung pathology. In this line of thinking it is re-
markable that the frequency of virus isolation from lung
tissues found in this study was significantly lower than
the frequency of virus isolation from the same organ
found in similar studies carried out with wild-type vi-
ruses [5,27] or even in a study carried out in adult boars
[28], indicating that the attenuation process might cause
changes related to cell tropism in the lung. These
changes most probably impair virus replication in PAM
until a point when replication in this cell type might be
completely abolished. This theory is supported by two
facts. The first one is that the presence of PRRSV in
PAM could only be confirmed by IHC in lung sections
of some pigs of groups A and B and always on day 21
pv. The second one is that PRRSV replication was dem-
onstrated in vitro in PAM cultures only in samples of
some pigs of groups A and B. Even more, vaccine viruses
of Pysvac-183 and Porcilis PRRS were never detected in
PAM, suggesting that those vaccine viruses might have
completely lost their ability to replicate in the natural
target cell of PRRSV while the other two vaccine strains
tested in this study can replicate, although poorly, in
PAM. It could be speculated that those viruses that re-
tain certain ability to replicate in PAM will be found in
the lung more frequently and that this replication in the
lung might be responsible for the development of lung
lesions. Thus, the mildness of the lesions recorded might
be a consequence of the limited replication of the vaccine
viruses in the lung and an indicator of attenuation. How-
ever, it should be kept in mind that differences in the
pneumotropism and pathogenicity of the parent viruses
could also account for the differences found in the devel-
opment of lung lesions in vaccinated pigs.
In order to compare viremia and viral organic distribu-
tion in pigs of different experimental groups, cultures of
MAP and MARC-145 cell line were used. When thenumber of viremic pigs, as determined by virus isolation
in MARC-145 cells, was compared between groups, the
number of positive pigs in groups C and D was lower
than in groups A and B, although differences were not
statistically significant. However, differences between
groups in the dynamics of viremia were significant.
Thus, most pigs of Groups A and B were already viremic
on day 3 of the experiment, while in Groups C and D
the onset of viremia was delayed and the first positive
animals were detected on day 6 pv. In the same way, the
number of positive tissue samples was higher in pigs of
groups A and B than in pigs of groups C and D. How-
ever, when the number of positive samples was com-
pared by tissue sample and by day, in most cases, the
differences were not statistically significant. This lack of
significance might be partly due to the low sample size.
Actually, when the total number of positive samples per
group, regardless of the tissue sample or necropsy day
considered, were compared, the differences were statisti-
cally significant between group B and all other groups.
When the dynamics of viremia and the organ distribu-
tion of vaccine strains were compared to those of field
strains using a similar model [5], no clear differences
between attenuated and wild-type viruses were found,
although the organic distribution appears to be more
limited in pigs exposed to vaccine strains. Thus, the per-
centage of positive organs in pigs exposed to wild-type
viruses ranged from 65.0% to 86.7% [5] while in the
present study only between 33.9% and 64.4% of the sam-
ples were positive. However, due to the existence of
remarkable differences between wild-type PRRSV isolates,
it is not possible to categorically state that the lower detec-
tion rate reported in this study is due to changes in the
replication capacity of the vaccine viruses occurring
during the attenuation process. To confirm this theory it
would be necessary to determine the organ distribution of
the parent strains and compare it to the attenuated
viruses.
Nonetheless, and despite the lower percentage of posi-
tive organs found in this study compared to organ distri-
bution of wild-type viruses, the organs in which PRRSV
was more frequently found were similar after infection
with attenuated and wild-type viruses, indicating that the
attenuation process might not have changed the tissue
tropism of the viruses substantially, with the notable
exception of the lung. Thus, the percentage of positive
lungs after wild-type PRRSV infection is typically close to
100% during the acute phase of the infection [5,28], while
in the present study the percentage of positive lung sam-
ples ranged from 20% to 66.7%. As previously stated, the
fact that replication of the vaccine strains is specially im-
paired in the lung compared to other organic locations
seems to indicate that during PRRSV attenuation by suc-
cessive passages in established cell lines, it can lose, at
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constitutes its target cell in the lung, specifically, the alveo-
lar macrophage [29,30].
The lower replication of vaccine viruses compared to
wild-type viruses in different organic locations might
reduce antigenic presentation, which might have conse-
quences on the development of a potent immune re-
sponse. Particularly, the low replication rate in the lung
might poorly stimulate the development of specific im-
mune response in the main target organ of PRRSV and
at mucosal sites. However, specific studies to demon-
strate whether attenuation and its subsequent effects in
organic replication of the vaccine viruses have any influ-
ence on the development of specific immune response
should be carried out because, to our knowledge, no in-
formation is available on this topic. Nonetheless, in most
of the studies carried out to determine the protection
elicited by different MLV PRRSV vaccines, the results
show that partial protection is the typical outcome upon
challenge of vaccinated pigs with different virulent iso-
lates [17,31,32], which is not significantly different from
the expected cross-protection between wild-type PRRS
viruses [33]. Consequently, it seems that impaired repli-
cation of vaccine viruses in the host is not clearly related
to the induction of a poor immune response and limited
protection. On the contrary, PRRSV variability seems
to play a major role in the lack of complete protection
between PRRSV isolates [33,34].
Finally, one of the parameters used to determine the
safety of MLV vaccines is the capability of the vaccine
strains to be shed by vaccinates and infect non-
vaccinated in-contact animals. In fact, the most signifi-
cant difference between the MLV vaccine strains used in
this study is their capability to be transmitted to senti-
nel pigs housed in direct contact with vaccinates. Thus,
the vaccine strains Ingelvac PRRS and Amervac PRRS
were transmitted to 100% and 88.9% of the sentinel
pigs, respectively, while vaccine strains Porcilis PRRS
and Pyrsvac-183 were found in only 44.4% and 22.2% of
in-contact pigs, respectively. These differences were sta-
tistically significant when the results of groups A and B
were compared to those of Group C and when the re-
sults of Group A were compared to those of Group D.
These data seem to be inconsistent with the relatively
homogenous shedding pattern by different routes found
in vaccinated animals, regardless of the vaccine strain
used in the immunization, and with the rather low fre-
quency of detection of vaccine viruses in the different
secretions analyzed (8.0%, 5.33%, 6.67% and 4.89% for
groups A, B, C and D, respectively).
These differences do not justify, at least completely,
the clear differences found in the transmission rate be-
tween the different experimental groups. Other factors,
like differences in cellular tropism, may play a role inthe final transmission capacity of a vaccine strain. In this
line of thinking, it should be kept in mind that the
route of exposure of sentinel pigs to the vaccine viruses
shed by vaccinated pigs is most likely the oro-nasal
route. Thus, only viruses able to infect a pig by this
route will be able to establish infection. Therefore,
there might be viruses capable of establishing an infec-
tion when they are injected to the pig by the IM route
that have difficulties in reaching cells susceptible to in-
fection when they reach the oro-nasal mucosa of the
pig in the portal of entry into the host. The theory that
not all vaccine viruses contained in a vaccine dose
might be able to infect a pig by the oro-nasal route is
supported by the results of a previous study carried out
in our laboratory in which not all growing pigs exposed
to 105 TCID50 of different vaccine strains by IN route
got infected, with the notable exception of pigs ex-
posed to the vaccine strain Ingelvac PRRS (unpub-
lished results).
Coherently with these findings, it is expected that
those viruses with a broader range of target cells will be
more efficient in the infection of susceptible pigs by dif-
ferent routes than those exhibiting a narrower range of
target cells. This hypothesis is supported by the fact that
the vaccine strains with lower capacity of replication
in vivo, and apparently unable to replicate in MAP cells,
were transmitted to a lower proportion of in-contact
pigs (i.e. groups C and D). In contrast, vaccine strains
that retained, although significantly impaired, their abil-
ity to replicate in MAP cells and were more extensively
distributed in vaccinated pigs, were transmitted to a
higher proportion of susceptible sentinels. Even more,
when the capacity of vaccine strain shedding by the in-
fected sentinel pigs was studied, it was found that the
frequency of shedding varied depending on the group
considered. Thus, the shedding rate by infected sentinel
pigs of Group A was higher than by vaccinated pigs of
any of the experimental groups and sentinel pigs of all
other groups. In addition, the shedding rate was similar
between vaccinated and infected sentinel pigs of Group
B. On the contrary, the shedding rate by infected senti-
nels of groups C and D was lower than by vaccinated
pigs of the same groups. These differences, although not
statistically significant, might indicate that the vaccine
strain that was the most frequently shed and transmitted
to in-contact pigs retained its ability to be shed, and
maybe transmitted to further pigs, after replication in
non-vaccinated pigs. On the contrary, the shedding of
vaccine strains by sentinels of groups C and D was poor
and restricted to a low number of pigs. Thus, the data
presented point towards the maintenance of some of the
vaccine strains in the pig population and towards the
dying out of the infection by others. However, these re-
sults should be considered carefully, especially since the
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study. This was due to limitations in the experimental
design of the study that focused mainly on the deter-
mination of the residual virulence of the vaccine strains
compared (measured by their ability to cause disease
and lesions in vaccinated pigs and by their organic dis-
tribution) and not only on the transmission capability of
each vaccine strain.
Although clinical signs were never observed in infected
sentinel pigs of any group, indicating that vaccine strains
had not significantly changed their virulence after one
in vivo passage, specific studies to determine the transmis-
sibility of each vaccine strain should be designed in the
future. This is so because the transmission capability of a
vaccine strain might be very relevant to its safety due to
the fact that the maintenance of a vaccine virus in a popu-
lation might increase the risk of reversion to virulence. In
fact, it has been suggested that genetic reversion to viru-
lence is a gradual process occurring with prolonged pas-
sage time of a vaccine strain in the field [16]. This process
might be facilitated in the case of PRRSV by its high muta-
tion rate [35,36]. Consistent with this theory is the de-
scription of virulent revertants of some vaccine strains in
different countries. Although some of those viruses have a
limited virulence [37] in other cases revertants are able to
cause clinical signs in experimentally infected pigs [38].
In the light of these results, and despite the fact that in-
fected sentinel pigs did not show any clinical sign, it would
be sensible to prevent, as much as possible, direct contact
between recently vaccinated and unvaccinated/susceptible
animals under farm conditions to avoid the possibility of
vaccine virus transmitting from pig-to-pig. Thus, it would
be advisable to vaccinate at the same time all animals in a
batch and keep them in isolation the following weeks,
avoiding contact with non-vaccinated pigs. This relatively
simple management measure might help to avoid the risk
of transmission to in-contact pigs that seems to be inher-
ent to PRRSV vaccine strains.
In conclusion, all vaccine strains compared in this study
can be considered clinically safe. However, some differ-
ences were found in virological parameters. The onset of
viremia was delayed in pigs of groups C and D, indicating
some difficulties in the initial in vivo replication of these
vaccine viruses. Besides, they were not detected in PAM
cultures or in lung sections by IHC, indicating that these
viruses might have lost their ability to replicate in PAM
cells. This reduced ability to replicate in PAM cells found
in this study might be related to the lower transmission
rate recorded for these two vaccine strains, maybe due to
a difficulty in establishing infection when these viruses
reach the mucosal surfaces of the host.Competing interests
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